Dragon Pharma Adds Finasteride and Hexarelin to Product Line
Dragon Pharma Adds Finasteride and Hexarelin to Product Line – INT Warehouse Only
Dragon Pharma has officially released two new products to its international catalog: Finasteride 5 mg oral tablets and Hexarelin 5 mg peptide vials. These compounds are now available for global customers via INT warehouse shipping, while domestic U.S. stock is expected within the next several weeks.
Product Overview
Finasteride (5 mg, 100 tablets per sachet)
Finasteride is a 5-alpha-reductase inhibitor commonly used in post-cycle therapy (PCT) to reduce DHT conversion. It is known for its applications in hair preservation and prostate health. Dragon Pharma's formulation provides 5 mg per tablet, with 100 tablets per resealable sachet.
Customers interested in post-cycle hair management or DHT modulation may consider this oral option from Dragon Pharma.
Drug Class: 5α-Reductase Inhibitor
Active Substance: Finasteride
Strength: 5 mg/tablet
Amount: 100 tablets
Active Life: 4–6 hours
Average Dose: 1–5 mg/day
Liver Toxicity: Low
Aromatization Rate: None
Anabolic Rate: None
Androgenic Rate: Indirectly Reduced via DHT Blockade
Manufacturer: Dragon Pharma
Hexarelin (5 mg, lyophilized peptide vial)
Hexarelin is a growth hormone–releasing peptide (GHRP) that stimulates endogenous GH secretion. Often used in performance and anti-aging protocols, it is administered in cycles of 4 to 6 weeks. Each 2 mL vial from Dragon Pharma contains 5 mg of lyophilized Hexarelin powder for reconstitution.
Users exploring peptide cycling or GH pulse therapies can learn more about this new Hexarelin vial option.
Drug Class: Growth Hormone Secretagogue (GHS)
Active Substance: Hexarelin (Examorelin)
Strength: 5 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: ~4–6 hours
Average Dose: 100–200 mcg/day (split doses)
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: Moderate (via GH/IGF-1 axis)
Androgenic Rate: None
Manufacturer: Dragon Pharma
Availability
- International Warehouse: Orders are shipping now with 7–21 day delivery windows depending on destination and customs
- Domestic U.S. Warehouse: Currently unavailable; expected ETA within 2–3 weeks
Testing and Verification
According to Dragon Pharma representatives, both compounds have been internally tested for identity and purity under GMP standards. Third-party lab test results have not yet been published but are reportedly pending for the current batches.
External References
- Finasteride: DHT Inhibition and Androgenic Control
- Hexarelin's Role in GH Secretion: A Clinical Overview
Commentary
Both Finasteride and Hexarelin have been used off-label by performance-enhancing drug (PED) users for years, but Dragon Pharma's decision to formalize these compounds in its catalog reflects broader market demand for pharmaceutical-grade support compounds.
This rollout also aligns with Dragon Pharma's recent push to expand its peptide and hormone modulation lineup, potentially signaling more diverse health-focused releases to come.
Customers Feedbacks
Please leave your feedback on products or service below.
Thank you beforehand.